Drug Profile
Research programme: acute coronary syndromes therapy - Trigen
Alternative Names: Antiplatelet therapies - Trigen; PR 10Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Trigen Holdings AG
- Class
- Mechanism of Action Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Acute coronary syndromes; Thrombosis
Most Recent Events
- 21 Feb 2008 This programme is still in active development
- 01 Nov 2005 Preclinical trials in Acute coronary syndromes in United Kingdom (unspecified route)
- 01 Nov 2005 Preclinical trials in Thrombosis in United Kingdom (unspecified route)